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Purpose. To develop an aerosol system for efficient local lung delivery of chemotherapeutics where
nanotechnology holds tremendous potential for developing more valuable cancer therapies. Concur-
rently, aerosolized chemotherapy is generating interest as a means to treat certain types of lung cancer
more effectively with less systemic exposure to the compound.
Methods. Nanoparticles of the potent anticancer drug, paclitaxel, were controllably assembled to form
low density microparticles directly after preparation of the nanoparticle suspension. The amino acid, L-
leucine, was used as a colloid destabilizer to drive the assembly of paclitaxel nanoparticles. A
combination chemotherapy aerosol was formed by assembling the paclitaxel nanoparticles in the
presence of cisplatin in solution.
Results. Freeze-dried powders of the combination chemotherapy possessed desirable aerodynamic
properties for inhalation. In addition, the dissolution rates of dried nanoparticle agglomerate
formulations (∼60% to 66% after 8 h) were significantly faster than that of micronized paclitaxel
powder as received (∼18% after 8 h). Interestingly, the presence of the water soluble cisplatin
accelerated the dissolution of paclitaxel.
Conclusions. Nanoparticle agglomerates of paclitaxel alone or in combination with cisplatin may serve as
effective chemotherapeutic dry powder aerosols to enable regional treatment of certain lung cancers.
KEY WORDS: cisplatin; combination chemotherapy; dry powder; nanoparticle agglomerates; paclitaxel.
INTRODUCTION
Lung cancer is the second most prevalent type of cancer
and the most common cause of cancer-related death world-
wide (1–3). Inefficient delivery of anticancer drugs to the
disease site after intravenous or oral administration is a
probable cause for the limited efficacy of some chemo-
therapeutics. Subsequently, the outcome for the treatment
of lung cancer has not significantly progressed in recent
history and the cure rate remains one of the lowest among all
malignancies (4).
Currently, the most common application of aerosol
therapy is regional drug delivery for airway and parenchyma
lung diseases; however, there is also expanding interest in
using the lung for systemic drug delivery (5). Dry powder
inhalers (DPI) are emerging as a preferred drug delivery
method compared to metered dose inhalers and nebulizers
due to the improved stability of dry powders and the ease of
use of the device (6,7). Inhalation is an attractive delivery
route for chemotherapeutics as it offers several advantages
over systemic and oral routes, including the probability of
regional drug delivery to the lungs and airways. High local
drug concentration may lower therapeutic doses, reduce
systemic side effects, reduce the metabolic degradation of
drugs in the liver, and offer noninvasive delivery (8,9).
Nanoparticle formulation of anticancer drugs has
become an important research area in cancer therapy that
may ultimately provide a way of sustained, controlled and
targeted drug delivery to improve the therapeutic effect and
reduce the side effects of the formulated drugs (10–12). For
example, dissolution of poorly water soluble drug nano-
particles can be rapid and subsequently, drug bioavailability
may be improved (13–15). However, the properties of
nanoparticles can make them difficult to process into dry
powders (16–19).
Aerosolized chemotherapy has to be precisely delivered
at a therapeutic concentration to the target area to be
effective (8). Delivery of pharmaceutical aerosols to the deep
lung presents significant challenges to a formulator (20).
Aerosol particle size is one of the vital determinants of
aerosol dose and distribution in the lungs (21). To reach the
peripheral airways and deposit in the alveolar region of the
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lung, aerosol particles need to be ∼1–5 μm in aerodynamic
diameter. Particles larger than 5 μm usually deposit in the oral
cavity or upper airways, from which they are easily cleared. In
contrast, particles smaller than 0.5 μm may be exhaled, since
they settle very slowly (22). In addition, such nanoparticles
can be highly cohesive due to the high surface area to mass
ratio of the particulates. Cohesive systems pose a problem as
uncontrolled agglomeration may lead to formulation varia-
tions and a decrease in dosing efficacy (18,23).
Recently, therapeutic interventions using combined che-
motherapeutic drugs have emerged in cancer treatment as
they have been proven to be more effective than a single drug
(24–26). Combination chemotherapy remains the cornerstone
of treatment for both limited-stage and extensive-stage small
cell lung cancer (SCLC) (27,28). In the context of non-small
cell lung cancer (NSCLC), drug combinations most frequently
used for initial chemotherapy are cisplatin or carboplatin
combined with other chemotherapeutic drugs such as pacli-
taxel (24). Higher response rates and a statistically significant
improvement in survival were observed in a study of
paclitaxel/cisplatin combination compared to many other
cisplatin combinations. There was also a trend towards
improved 1-year survival (29). Therefore, inhaled paclitaxel
alone or in combination with cisplatin may be desirable.
Paclitaxel is an antineoplastic agent that works by
inhibiting cellular growth through the promotion and stabili-
zation of microtubule assembly by non-covalent interaction
with tubulin, thereby blocking cell replication (30,31). It is a
powerful anticancer drug with an established activity against a
number of human, solid tumors and has become standard
treatment as single agent or in combination chemotherapy for
the management of advanced breast, ovarian and non-small-
cell lung cancer (32). Paclitaxel possesses an extremely low
aqueous solubility (<0.03 mg/mL) (33). Consequently, the
formulation of paclitaxel has been a challenge, and many
approaches have been tested or are under exploration. Signif-
icant advances in cancer treatment may be realized by the
discovery and development of novel paclitaxel dosage forms
with improved efficiency, reduced toxicity, and an expanded
spectrum of activity (34). Cisplatin [cis-diamminedichloro
platinum (II)] has been one of the most widely used and
effective cytotoxic agents in the treatment of malignancies of
lung, head and neck, testis, and ovarian cancers (35–37).
Cisplatin is still the backbone of chemotherapy combinations
in NSCLC, and several combinations of cisplatin-based chemo-
therapy are used in the current treatment of this disease (25).
A promising dry powder aerosol of paclitaxel as a single
agent or in combination with cisplatin was formulated using
an approach to controllably assemble paclitaxel nanoparticles
into low-density microparticles. Paclitaxel nanoparticle sus-
pensions were formulated using appropriate surfactants for
pulmonary administration that control the size and surface
charge of the prepared nanoparticles. The resulting colloidal
suspensions were destabilized via ionic charge interactions
using a suitable flocculating agent followed by lyophilizing the
nanoparticle agglomerates into dry powder. In the case of the
combined therapy formulation, an aqueous solution of
cisplatin was injected into the paclitaxel nanoparticle suspen-
sion followed by addition of the agglomerating agent. These
micron-sized agglomerates were easily aerosolized and
exhibited enhanced dissolution. The powders reported here
offer a novel formulation for localizing chemotherapy in the
treatment of lung cancer.
MATERIALS AND METHODS
Materials
Paclitaxel (PX), cisplatin (CP), L-α-phosphatidylcholine
(lecithin; Lec), cetyl alcohol (CA), L-leucine (Leu), polyvi-
nylpyrrolidone (PVP K90, Mw∼36,000) and sodium chloride
(NaCl) were purchased from Sigma Chemicals Co, St Louis,
MO, USA. Pluronic F-127 (PL, Mw∼12,220) was purchased
from BASF, The Chemical Company, Shakopee, MN, USA.
Polyvinyl alcohol (PVA; Mw=22,000, 88% hydrolyzed) was
purchased from Acros Organics, New Jersey, NJ, USA.
Potassium dihydrogen phosphate (KH2PO4), disodium hy-
drogen phosphate (Na2HPO4), acetone, ethanol, nitric acid
and acetonitrile were purchased through Fisher Scientific,
Fair Lawn, NJ, USA. Floatable dialysis membrane units
(Regenerated Cellulose Membranes, manufactured from
natural cellulose reconstituted from cotton linters, Mw cut-
off=10,000 Da) were obtained from Spectrum Laboratories
Inc., Rancho Dominguez, CA, USA. A549 cells were
obtained from the American Type Culture Collection
(ATCC, Rockville, MD). The cell culture medium (Ham’s
F-12 Nutrient Mixture, Kaighn’s modified with L-glutamine)
was purchased through Fisher Scientific. Fetal bovine serum
(FBS) was purchased from Hyclone, Logan, UT, USA.
Penicillin–streptomycin was purchased from MB Biomedical,
LLC, Winnipeg, MB, USA. Trypsin–EDTA was purchased
through Gibco, Carlsbad, CA, USA. MTS reagent [tetrazo-
lium compound; 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxyme-
thoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt]
was purchased from Promega, Madison, WI, USA. Double-
distilled water was used throughout the study, provided by an
EASYpure® RODI (Barnstead International, Model #
D13321, Dubuque, Iowa, USA).
Fabrication of Paclitaxel Nanoparticles
Nanosuspensions were generated using a precipitation
technique by slow injection of 2.5 mL acetone solution of
paclitaxel, 0.1% w/v, in 25 mL distilled water at a rate of
1 mL/min under ultrasonication (probe-type sonicator, Fisher
Scientific, Sonic Dismembrator) operating at an amplitude of
46%. Various surfactants were selected for the formulation of
nanoparticles including hydrophobic (cetyl alcohol), hydro-
philic (PL, PVA and PVP K90) and amphoteric (lecithin).
The hydrophobic and amphoteric surfactants were added to
the drug solution and the contents were sonicated in a bath-
type sonicator (Branson 3510) for 30 min to allow complete
solubilization of the drug and the surfactants. Hydrophilic
surfactants were added to the aqueous phase. Surfactants
were used individually or in combination as reported.
Characterization of the Prepared Nanoparticles
The particle size and zeta potential of the nanosuspen-
sions were determined by dynamic light scattering (Broo-
khaven, ZetaPALS, Holtsville, NY, USA). Particle size was
measured using distilled water while zeta potential measure-
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ments were performed using 1 mM KCl solution. Triplicate
measurements of all samples were performed.
Combination Chemotherapy of Paclitaxel Nanoparticles/
Cisplatin Powder
The combined chemotherapeutic formulations were
prepared by slow injection of 2.5 mL cisplatin aqueous
solution to the paclitaxel nanosuspension (F1) during homog-
enization at 25,000 rpm. The two drugs were combined, at a
ratio of 3:2 w/w, paclitaxel:cisplatin (29,32).
Agglomeration of Paclitaxel Nanoparticles and Combined
Chemotherapy Formulation
Nanoparticle agglomerates were prepared by addition of
L-leucine powder to the nanosuspensions followed by homog-
enization at 25,000 rpm for 30 s. The amount of L-leucine
added was adjusted to a paclitaxel:leucine ratio equal to 1:1.
The size of the nanoparticle agglomerates was measured in
Isoton diluent using a Coulter Multisizer 3 (Beckman Coulter
Inc., Miami, FL, USA) equipped with a 100 μm aperture after
3 h of incubation with the flocculating agent. The suspensions
were kept overnight at room temperature to allow evapora-
tion of acetone and then frozen at −80°C and transferred to a
freeze dryer (Labconco, FreeZone 1, Kansas City, MO,
USA). Drying lasted for 36 h to remove all appreciable water
content. Lyophilized powder was stored at room temperature
for further characterization.
Characterization of the Selected Nanoparticle Agglomerates
Determination of Particle Size Distribution
The particle size of the nanoparticle agglomerates
immediately after flocculation as well as the resuspended
lyophilized powder was measured using a Coulter Multisizer
3.
Angle of Repose and Bulk Density Measurements
The flow properties of the nanoparticle agglomerates
were assessed by angle of repose measurement of the dried
powders (38). The fixed-height cone method was used. A
glass funnel with cut stem surface of 5 mm internal diameter
was fixed at 2.5 cm height over a flat surface. The powders
were allowed to flow gently through the funnel until a cone
was formed and reached the funnel orifice. The flow of
powder was then stopped and the average diameter of the
formed cone (D) was measured. The angle of repose was
calculated by the equation: tan θ=height/radius.
Furthermore, the bulk and tap densities were determined
for the dried powders and compared with that of the
paclitaxel powder as received. Ten milligrams of lyophilized
powders were weighed and poured into a 10 mL graduated
measuring cylinder. The bulk volume occupied (Vb) was
recorded. The measuring cylinder was tapped until a constant
value was obtained and the tap volume was recorded (Vt).
The process was repeated at least three times and the average
was taken in each case. The bulk (ρbulk) and tap (ρtap)
densities of powders were calculated by dividing the weight
by the corresponding bulk volume or tapped volume
recorded. Carr’s “percent compressibility” and Hausner ratio







>bulk , respectively. Angle of repose, Hausner
ratio and Carr’s index are considered indirect methods of
quantifying powder flowability. The following ranges are
indicative of good flow properties: 25–30° for angle of repose,
<1.25 for Hausner ratio, 5–15% for Carr’s index (38,39).
Measurement of Mass-median Aerodynamic Diameter
The aerodynamic size distributions of the agglomerate
powders were measured directly from lyophilized powders by
time-of-flight measurement using an Aerosizer LD (Amherst
Instruments, Hadley, MA, USA) equipped with a 700 μm
aperture operating at 6 psi.
The theoretical mass–mean aerodynamic diameter
(daero) of the nanoparticle agglomerates was determined from










Where dgeo=geometric diameter, γ=shape factor (for a spher-
ical particle, γ=1; for aerodynamic diameter calculations, the
particles in this study were assumed to be spherical), ρ=particle
bulk density and ρref=water mass density (1 g/cm
3). Tapped
density measurements underestimate particle bulk densities
since the volume of particles measured includes the interstitial
space between the particles. The true particle density, and the
aerodynamic diameter of a given powder, is expected to be
slightly larger than reported (42).
In Vitro Aerosolization Performance
Aerodynamic properties of the dry powders were investi-
gated in vitro using a Tisch Ambient Cascade Impactor (Tisch
Environmental, Inc., Village of Cleves, OH, USA). The study
was carried out by applying ∼10 mg dry powder manually into
the orifice of the instrument operated at an air flow rate of
∼30 L/min for 10 s to simulate an inspiration. Cut-off particle
aerodynamic diameters of each stage of the impactor were: pre-
separator (10.00 μm), stage 0 (9.00 μm), stage 1 (5.8 μm), stage 2
(4.7 μm), stage 3 (3.3 μm), stage 4 (2.1 μm), stage 5 (1.1 μm),
stage 6 (0.7 μm), stage 7 (0.4 μm) and filter (0 μm). Nanoparticle
agglomerates deposited on each stage of the impactor were
determined by measuring the difference in weight of filters
placed on the stages. The percent emitted fraction (%EF) and
fine particle fractions of the total dose (FPFTD) were then
calculated (42–44). The percent emitted fraction was deter-
mined from the following equation:
% Emitted fraction %EFð Þ
¼ Total particle mass collected from the stages of the impactor
Total particle mass entered into the impactor
100
The fine particle fraction of the total dose (FPFTD) was
calculated as the percentage of aerosolized particles that
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reached the lower seven stages of the impactor (corresponding
to aerodynamic diameters below 5.8 μm), or the lower five
stages (corresponding to aerodynamic diameters below 3.3 μm)
according to the following equation (42):
% Fine particle fraction ðFPFTDÞ
¼ Powder mass recovered from terminal stages of the impactor
Total particle mass recovered in the impactor
100
Furthermore, the mass median aerodynamic diameter, MMAD,
and geometric standard deviation, GSD, were obtained by a
linear fit of the cumulative percent less-than the particle size
range by weight plotted on a probability scale as a function of
the logarithm of the effective cut-off diameter (45,46). GSD of





where dn is the diameter at the nth percentile of the cumulative
distribution.
Concerning the dry powder of the combined chemother-
apy, drug concentrations deposited on each stage of the
impactor were determined. The powder deposited on each
stage was collected after weighing and dissolved in 10 mL
ethanol. The dispersion was sonicated in a bath-type soni-
cator (Branson 3510) for 1 h. Then the solution was
centrifuged (Beckman, Avanti™) at ∼15,000 rpm for 30 min
and the amount of paclitaxel in the supernatant was
determined using a reverse-phase HPLC method (12,47)
while cisplatin content was detected by analyzing platinum
metal in both supernatant and precipitate after dissolving the
precipitate in 10 mL phosphate buffered saline (PBS, pH 7.4)
using an atomic absorption spectrophotometer (Spectra AA
220G, Varian) (36,37,48).
Imaging of Particles by Transmission Electron Microscopy
Image data was used to corroborate the size of nano-
particles and nanoparticle agglomerates and to observe their
morphological aspects. Transmission electron micrographs
(TEM) were obtained for paclitaxel nanoparticles and
nanoparticle agglomerates using a JEOL 1200 EXII trans-
mission electron microscope. Initially, carbon-coated grids
(Electron Microscopy Sciences) were floated on a droplet of
the suspensions on a flexible plastic film (Parafilm), to
permit the adsorption of the particles onto the grid. After
this, the grid was blotted with a filter paper and air dried for
1 h.
Thermal Analysis
Nanoparticles and nanoparticle agglomerates were in-
vestigated by differential scanning calorimetry (DSC, Q100
Universal V4.3A TA instruments) and thermogravimetric
analysis (TGA, Q50 Universal V4.3A TA instruments). For
DSC analysis, a small portion (6–10 mg) of the lyophilized dry
mass was sealed and placed in an aluminum pan and heated
at a constant rate of 10°C/min over a temperature range of
25–300°C for paclitaxel powder as received, lecithin, L-
leucine, nanoparticles and nanoparticle agglomerate formu-
lation (F2). An inert atmosphere was maintained by purging
with nitrogen at 50 mL/min. For TGA, samples weighing 5±
2 mg were scanned at a rate of 10°C/min with a nitrogen flow
rate of 40 mL/min.
Determination of Process Yield and Paclitaxel Loading
in Nanoparticle Agglomerates
Nanoparticle agglomerate dry powders were quantified
and the yield was calculated for each formula using the
following expression:
% Process yield ¼ Recovered mass
Mass entered into the experiment
 100
Paclitaxel loading in the dry powders was assessed by
dispersing one mg of the lyophilized powder in 10 mL
ethanol. The dispersion was sonicated in a bath-type soni-
cator for 30 min. Then the solution was centrifuged at
∼15,000 rpm for 30 min to remove insoluble ingredients and
the amount of paclitaxel in the supernatant was determined
using a reverse-phase HPLC method. On the other hand,
cisplatin content in the combination formula was detected by
analyzing platinum metal in both supernatant and residue
after dissolving the residue in 10 mL PBS (pH 7.4) using the
atomic absorption spectrophotometer. Drug loading was
defined as follows (47,49):




The dissolution of the prepared nanoparticles and
nanoparticle agglomerates was determined under sink
condition and compared with the dissolution characteristics
of the drug powder as received. The dissolution of paclitaxel
was carried out at 37±0.5°C in a 1 L beaker. Lyophilized
powder (∼10 mg) was dispersed in 10 mL PBS, pH 7.4 and
was suspended into a floatable dialysis membrane unit (Mw
cut-off=10,000 Da). The unit was allowed to float in 500 mL
of PBS and the whole assembly was stirred at a constant
speed (100 rpm) using a magnetic stirrer (Barnstead,
Thermolyne MIRAK™). At predetermined time intervals
for a total period of 8 h, serial samples (1 mL) of the
medium were withdrawn from the dialysis bag and replaced
with fresh medium. Then the samples were centrifuged for
30 min at ∼13,000 rpm. The nanoparticle-free supernatant
was removed and the residue was extracted with 1 mL of
ethanol (12,49). The ethanol extract was analyzed for
paclitaxel concentration using the reverse-phase HPLC
method. In the case of the combined chemotherapy formula,
the supernatant was analyzed for cisplatin concentration
using the atomic absorption spectrophotometer. Studies
were conducted in triplicate. Phosphate buffered saline
(PBS, pH 7.4) was composed of 2.38 g Na2HPO4, 0.19 g
KH2PO4 and 8 g NaCl.
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HPLC Analysis of Paclitaxel
A reverse-phase HPLC method was used for quantify-
ing paclitaxel samples (n=3). A Shimadzu HPLC system
including a solvent delivery pump (Shimadzu LC-10AT), a
controller (Shimadzu SCL-10A), an autoinjector (Shimadzu
SIL-10AxL), and a UV detector (Shimadzu SPD-10A) was
used in this study. The peak areas were integrated using
Shimadzu Class VP (Version 4.3). A 4.6 mm×125 mm long
Kromasil 100-5 C-8 column was used. During the assay,
paclitaxel was eluted isocratically at a mobile phase flow
rate of 0.9 mL/min and monitored with a UV detector
operating at 228 nm. The mobile phase for the assay
consisted of an acetonitrile and water mixture (50:50 v/v)
(12,47). The run time for the assay was 20 min, and the
retention time for paclitaxel was 10.7±0.1 min.
Atomic Absorption Spectroscopy for Cisplatin (AAS)
Cisplatin samples (n=3) were diluted 200-fold with 0.1%
nitric acid for analysis. Analysis was performed on a Varian
SpectrAA GTA-110 with graphite furnace and partition
tubes. Samples (21 μL) were injected using the autosampler,
followed by 19 μL of 0.1% nitric acid. Every ten samples were
bracketed by calibration standards at 50, 75, and 150 ng/mL,
and a quality control sample (50 or 75 ng/mL) every five
samples. The furnace program was as follows: ramp 25 to
80°C, hold 2 s, ramp to 120°C, hold 10 s, ramp to 1,000°C,
hold 5 s, ramp to 2,700°C, hold 2 s, cool to 25°C over 20 s.
The graphite partition tube was cleaned every 500 injections
samples by baking at 2,800°C for 7 s. Argon was used as the
injection and carrier gas.
Cytotoxicity Assessment
The cytotoxicity of paclitaxel nanoparticle and nano-
particle agglomerate formulations was evaluated using the
CellTiter 96® Aqueous Cell Proliferation Assay (Promega)
and compared with paclitaxel powder as received, lecithin,
PVP K90, L-leucine, physical mixtures of the ingredients used
for the preparation of the selected formulas (F1 and F2) and
blank nanoparticle agglomerates. In this experiment, A549
cells were cultured for 2 days. Then 8×104 A549 cells/well
were seeded in 96-well microtiter plates and incubated for
24 h before adding the formulas. The tested chemicals were
suspended in water and the A549 cells were incubated with
serial dilutions of these chemicals (0.000625–5 mg/mL). At
the end of the incubation period (24 h), 20 μL of MTS
reagent solution was added to each well and incubated for 3 h
at 37°C. The absorbance was measured at 490 nm using a
microtiter plate reader (SpectraMax, M25, Molecular Devices
Corp., Sunnyvale, CA, USA). The percentage of viable cells




Precipitation methods are able to create nanoparticles of
poorly water soluble drugs such as paclitaxel (52–54). Using
this technique, nanoparticle suspensions were designed with
different types and concentrations of surfactants, individually
or in combination, as a means to control the particle size and
surface charge of the prepared nanoparticles. Surfactants
were chosen from a selection of excipients likely to be
suitable for inhalation and proven to be safe for human use
in certain concentrations (6).
Based on particle size and polydispersity measure-
ments, the most successful surfactant combination and ratios
for generating paclitaxel nanosuspension turned out to be
the formulations; reported in Table I. These surfactant
combinations yielded small paclitaxel particle size (298–
358 nm). Formula, F1, was chosen for the combination with
cisplatin as it showed smaller particle size and narrower size
distribution with higher yield compared to the other
formulas. A small change in zeta potential was observed
with different types of surfactants and the values ranged
from ∼22–25 mV (Table II). The charged surface of the










F1 0.1 0.02 0.01
F2 0.1 0.02
F3 0.1 0.02 0.01







F1a 299±10 25.1±0.7 0.04±0.03
F2b 339±14 24.7±1.5 0.18±0.1
F3c 359±8.0 22.4±1.0 0.31±0.1
a F1=0.1:0.02:0.01; PX:Lec:PVP K90
b F2=0.1:0.02; PX:Lec
c F3=0.1:0.02:0.01; PX:Lec:CA




F1a F2b F1 Combc
Geometric particle size




(μm) of lyophilized NAd
4.8±1 5.4±2 5.9±3
MMADA
e of lyophilized NAd 1.5±0.1 1.7±0.4 1.8±0.01
MMADt
f of lyophilized NAd 1.1±1 1.2±1 1.5±0.1
a F1=0.1:0.02:0.01; PX:Lec:PVP K90
b F2=0.1:0.02; PX:Lec
c F1 Comb=3:2; PX:CP
dNA: nanoparticle agglomerates
eMMADA: mass median aerodynamic diameter obtained from
Aerosizer
fMMADt: theoretical mass mean aerodynamic diameter calculated
from density measurements
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nanoparticles, provided by the surfactants, offered the
potential for destabilizing this colloid via interaction with a
flocculating agent to form nanoparticle agglomerates.
Agglomeration of Paclitaxel Nanoparticles
The mechanism to control nanoparticle agglomeration is
mainly driven by leveraging the competitive processes of
attraction (van der Waals force) and repulsion (electrostatic
repulsive force or steric hindrance or both). If particles are
mainly stabilized electrostatically, disruption of the electro-
static double layer surrounding the particles will result in the
agglomeration of nanoparticles. The addition of flocculating
agents has also been speculated to decrease the cohesion
between particles (e.g. nanoparticle agglomerates). It is
thought that these agents may interfere with weak bonding
forces between small particles, such as van der Waals and
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Fig. 1. The particle size distributions of paclitaxel nanoparticle
agglomerates and F1 combination in suspension after flocculation









































































Fig. 2. Aerodynamic size distributions of paclitaxel nanoparticle
agglomerates and F1 combination after lyophilization, for formula-
tions A F1, B F2 and C F1 combination.
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breakers” between the particles which are susceptible to
disruption in the turbulent airstream created during inhala-
tion (55,56).
Flocculation of paclitaxel nanoparticles and nanopar-
ticles combined with cisplatin resulted in the formation of
agglomerates ∼1–5 μm. The geometric size distribution of the
prepared nanoparticle agglomerates was measured in Isoton
diluent using a Coulter Multisizer 3. The average size of two
selected nanoparticle agglomerate formulations (F1 and F2)
and the combination chemotherapy (F1 comb) ranged from
∼2–4 μm (Table III). However, F3 showed very large
agglomerates and a broad size distribution (∼5–8 μm). This
may be attributed to the surfactant mixture, which is an
important determinate of the agglomeration of drug nano-
particles. Therefore, F3 was excluded from further character-
ization. The size distributions of resuspended lyophilized
powders were slightly broader and the average particle size
was increased to some extent when compared to the nano-
particle agglomerates in suspension prior to lyophilization
(Table III and Fig. 1). This may be due to the deposition of
nanoparticles on agglomerates during lyophilization or to
cohesion between agglomerates as a result of drying (57).
Furthermore, it was clear that the combination lyophilized
powders had a broader distribution compared to the other
two formulations (F1 and F2). This may have resulted from
the agglomeration of powders of different particle sizes
including paclitaxel nanoparticles and cisplatin powder, or
from the uncontrolled formation of cisplatin-rich particles.
The aerodynamic diameter (daero) is regarded as an
important physical parameter that predicts the site of aerosol
deposition within the lungs (58). The aerodynamic diameter
of the flocculated nanoparticles, measured by an Aerosizer
LD, was found to be smaller than the geometric diameter and
the aerodynamic size distribution was narrower than the
geometric size distribution (Table III and Fig. 2). This reflects
the low density of the nanoparticle agglomerates.
The flow characteristics of the selected nanoparticle
agglomerates were also determined by calculating Angle of
repose, Hausner ratio and Carr’s index (Table IV). Nano-
particle agglomerates demonstrated improved and acceptable
flow properties. Improvement in flowability may be partially
explained by the reduced bulk and tap densities of the
nanoparticle agglomerates compared to that of the drug
powder as received. In addition, L-leucine has been reported
to reduce surface energy in dry powders and may improve
flowability in this case (59,60).
The theoretical mass–mean aerodynamic diameters
(daero) of the nanoparticle agglomerates, determined from
the geometric particle size and tap density were found to be
1.1, 1.2 and 1.5 μm for F1, F2 and F1 combination,
respectively (Table III). Paclitaxel nanoparticle agglomerates
with daero in this range may be expected to deposit primarily
in the alveolar region of the lungs (58). Aerosizer results and
theoretical MMAD calculations were confirmed by cascade
impaction studies at an air flow rate of ∼30 L/min (Fig. 3).
Most nanoparticle agglomerates were deposited in stages 5–7
of the cascade impactor which was indicative of efficient
aerosolization and a high fine particle fraction. However, F1
combination nanoparticle agglomerates exhibited some de-
position on stages 0 and 1.
The aerosolization efficacy was represented by the
percent emitted fraction (%EF), fine particle fraction of the
total dose (FPFTD), mass-median aerodynamic diameter
(MMAD) and geometric standard deviation (GSD). The high
emitted fraction of nanoparticle agglomerates obtained at the
tested flow rate (∼71–78%) suggested efficient aerosolization
of the powder (Table V).
Cascade impaction data suggested that the anticipated
total lung deposition (i.e. FPFTD <5.8 μm) was about 95%
and deep lung deposition (i.e. FPFTD<3.3 μm) was about 80%
for paclitaxel dry powder formulations, F1 and F2 (Table V).
However, F1 combination dry powders exhibited an estimat-
ed total lung deposition of 79% and deep lung deposition of
71%, which were slightly lower than that found for the dry
Table IV. Flowability Characteristics of Paclitaxel Nanoparticle Agglomerates (Values=Average±S.D.)
Formula no. Angle of repose (θ) Bulk density (g/cm3) Tapped density (g/cm3) Carr’s index (Ci %) Hausner ratio
Paclitaxel as received 27±1 0.2±0.1 0.3±0.01 19±0.03 1.3±0.04
Cisplatin as received 31±0.4 0.3±0.1 0.4±0.02 20±0.1 1.4±0.1
F1a 24±1 0.04±0.1 0.05±0.01 16±0.04 1.2±0.1
F2b 23±1 0.03±0.03 0.04±0.01 13±0.1 1.1±0.1
F1 Combc 32±2 0.05±0.003 0.06±0.01 18±0.1 1.2±0.2
a F1=0.1:0.02:0.01; PX:Lec:PVP K90
b F2=0.1:0.02; PX:Lec
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F2 = 0.1:0.02:0.1; PX:Lec:eu
F1 Comb= 3:2; PX:CP
PX: Paclitaxel powder as received      
CP: Cisplatin powder as received
Fig. 3. The distribution of paclitaxel and cisplatin powder as received
as well as nanoparticle agglomerate formulations deposited on the
stages of a cascade impactor at a flow rate of ∼30 L/min.
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powders containing paclitaxel alone. All formulas offered the
potential of high fine particle fraction suggesting excellent
aerosol performance (61).
The mass–mean geometric size of nanoparticle agglom-
erates ranged between 4.8 and 5.9 μm with a GSD of ∼2.3 μm
(Table V). Typical GSD values for aerosol particles are
between 1.3–3.0 (46). The mass-median aerodynamic diame-
ter (MMAD) of the selected nanoparticle agglomerates, as
calculated from the cascade impaction results (Table V) was
found to be close to that obtained from the Aerosizer and the
theoretical MMAD calculations (Table 3).
By chemically analyzing the powder of F1 comb that
deposited on each stage of the cascade impactor, it was clear
that the highest percent of paclitaxel and cisplatin was shown
in stage 6 (42.8% and 39.5) followed by stage 5 (27.6% and
22.4) and then stage 7 (13.4 and 11.6), respectively (Fig. 4).
However, cisplatin exhibited a slightly higher percent of
powder in stages zero and one than paclitaxel. This was
likely result of segregation of some larger cisplatin-rich
particles during drying.
Particle Imaging
Electron microscopy was used to study the morphology
of paclitaxel nanoparticles and nanoparticle agglomerate
formulations. Transmission electron micrographs (TEM) of
F1 nanoparticles illustrated slightly elongated nanoparticles
with smooth surfaces and a particle size around 300 nm
(Fig. 5A). TEM images of F1 nanoparticle agglomerates
showed that the nanoparticles were flocculated into micron
sized agglomerates of approximately 2–3 μm resembling
bundles of elongated paclitaxel particles (Fig. 5B). A TEM
image of the F1 combination showed the flocculation of
paclitaxel nanoparticles after drying with cisplatin (Fig. 5C).
The combination powders generally appeared slightly larger
and rough particles (presumably cisplatin) appeared to be
deposited on the rod-shaped paclitaxel particles.
Thermal Analysis (DSC and TGA)
The thermal properties of paclitaxel nanoparticles and
nanoparticle agglomerates of formula F2 were investigated by
differential scanning calorimetry (DSC) and thermogravimet-
ric analysis (TGA). The DSC curve of paclitaxel powder as
received exhibited a very small change in baseline around
60°C due to the presence of residual, probably absorbed or
nonstructural water. The curve also showed an endothermic
peak of melting at 220.7°C with an enthalpy change of
72.53 J/g just prior to an exothermic degradation peak
(Table VI and Fig. 6) (62). For lecithin and L-leucine
powders, there was a sharp melting endotherm at 168.2°C
and 323.7°C, respectively. No paclitaxel melting peak was
found in F2 nanoparticles. The curve also exhibited a small
change in baseline ∼60°C, probably due to the presence of
absorbed or nonstructural water (47). Paclitaxel in the nano-
particle agglomerates also exhibited a small change in
baseline at ∼60°C and a shallow broad endothermic peak at
the same position where the drug as received underwent a
melting phenomenon upon heating; however, the character-
istic peaks of the excipients were not apparent (Fig. 6). It was
also clear that there was a significant increase in the heat of
Table V. Cascade Impaction Results of Lyophilized Paclitaxel Nanoparticle Agglomerates (Values=Average±S.D.)
Characteristics of the lyophilized NAd
Formulations
F1a F2b F1 Combc Paclitaxel as received Cisplatin as received
At flow rate of ∼30 L/min % EFe 72±5 72±15 78±1 68±6 70±1
% FPFf <5.7 96±3 95±4 79±1 0.4±0.3 0.3±0.4
<3.3 84±3 80±5 71±1 0 0
MMADg 1.5±0.1 1.9±0.4 1.8±0.04 9.5±0.04 9.5±0.1
GSDh 2.2±0.1 2.3±0.1 2.2±0.2 1.9±0.1 3.5±0.1
a F1=0.1:0.02:0.01; Px:Lec:PVP K90
b F2=0.1:0.02; Px:Lec
c F1 Comb=3:2; PX:CP
dNA: nanoparticle agglomerates
e% EF: percent emitted fraction
f FPF: fine particle fraction
gMMAD: mass median aerodynamic diameter obtained from cascade impactor
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Fig. 4. The percent of paclitaxel and cisplatin in F1 combination
nanoparticle agglomerate formulation deposited on the stages of a
cascade impactor at a flow rate of ∼30 L/min.
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enthalpy compared to the pure drug. This may be indicative
of some re-crystallization of the drug during the agglomera-
tion process.
A systemic thermogravimetric analysis of paclitaxel
powder as received revealed a 0.97% weight loss over the
temperature range 10–200°C. The nanoparticles and nano-
particle agglomerates showed a higher weight loss of 2.45%
and 2.48%, respectively (Fig. 7). The expected weight loss for
paclitaxel dihydrate due to water evaporation is ∼4.3%,
which is approximately equivalent to two molecules of water
per molecule of paclitaxel and the weight loss of amorphous
paclitaxel was reported to be ∼0.7% (63). In this case, the
weight loss due to water evaporation (∼2.4%) by TGA may
reveal the presence of mixed morphologies of paclitaxel made
of both the dihydrate and amorphous or “as received”
crystalline forms.
Process Yield and Drug Loading
The process to agglomerate nanoparticles consistently
achieved a high yield (∼85–89%), which indicated efficient
processing with minimum batch variability. The loading effi-
ciency of paclitaxel in the prepared nanoparticle agglomerates
(F1, F2 and F1 comb) was found to be ∼85–93% (Table VII),
and that of cisplatin in F1 comb was ∼90%, thus demonstrating
minimal loss of drug during powder preparation.
Paclitaxel Nanoparticle and Nanoparticle Agglomerates
Showed Improved Dissolution Rates
Dissolution of paclitaxel from nanoparticles and nano-
particle agglomerates (F1 and F2) into PBS was faster than
that of the paclitaxel powder as received which achieved only
∼18.1% dissolved drug after 8 h (Table VII and Fig. 8A, B).
The cumulative percentage of the drug dissolved from nano-
particle agglomerates (Q8h) was found to be slower than that
of the nanoparticles. F1 nanoparticle and nanoparticle
agglomerate formulations exhibited faster drug dissolution
than F2 which may be due to the incorporation of the
hydrophilic surfactant, PVP K90.
Paclitaxel dissolution from the F1 combination was faster
than that of the F1 nanoparticle agglomerates and slightly
faster than that of the prepared nanoparticles in the first
80 min followed by similar dissolution behavior. This may be
due to the increase in the hydrophilicity of paclitaxel nano-
particle agglomerates as a result of the presence of the water
soluble cisplatin powder integrated within the agglomerates
(12). In addition, the slower dissolution behavior of paclitaxel
nanoparticles compared to paclitaxel nanoparticle agglomer-
ates in the F1 combination may be due to the aggregation of
some nanoparticles in suspension after preparation.
The dissolution behavior of cisplatin from the agglomer-
ated combination was also faster to some extent (∼100%
after ∼80 min) than cisplatin powder as received which
B CA
Fig. 5. Transmission electron micrographs of A F1 nanoparticles B F1 nanoparticle agglomerates and C F1 combination.
Table VI. DSC Peak Integrations for Paclitaxel, Lecithin and L-
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Fig. 6. Differential scanning calorimetry (DSC) thermograms for
paclitaxel as received, nanoparticles (NP), nanoparticle agglomerates
(NA), lecithin and L-leucine as received.
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achieved ∼100% after 2 h (Table VII and Fig. 8C). These
findings may be due to the merging of cisplatin powder with
paclitaxel nanoparticle agglomerates, which may result in a
slight increase in the particle surface area thus enhancing the
dissolution rate of cisplatin (14).
Linear regression analysis of the paclitaxel dissolution
data concluded that the drug was released by the Higuchi
diffusion mechanism in all cases. A two-way Analysis of
Variance (ANOVA) was performed to determine the signif-
icance of differences in paclitaxel dissolution kinetics. Signif-
icant differences existed between nanoparticles, nanoparticle
agglomerates and paclitaxel powder as received. This sug-
gested a significant improvement (P<0.05) in the dissolution
behavior of the nanoparticles and nanoparticle agglomerates
when these were individually compared to the paclitaxel
powder as received.
Measurement of Cytotoxicity
The cytotoxic effect of the different paclitaxel formula-
tions was evaluated and compared to paclitaxel powder as
received, lecithin, PVP K90, L-leucine, physical mixtures of
F1 and F2 components and blank F1 and F2 nanoparticle
agglomerates. It was clear that the excipients; lecithin, PVP



















Fig. 7. Thermogravimetric analysis (TGA) for paclitaxel as received,
nanoparticles (NP), and nanoparticle agglomerates (NA).









of PX and CP
in the lyophilized
NAd
85±4% 86±9% 93±4% (PX)
90±5% (CP)
Q8h
f NPe 66±2% 61±13% n/a
Q8h
f NAd 44±4% 40±3% 61±5% (PX)
100±2% (CP)
a F1=0.1:0.02:0.01; PX:Lec:PVP K90
b F2=0.1:0.02; PX:Lec
c F1 Comb=3:2; PX:CP
dNA: nanoparticle agglomerates
eNP: nanoparticles
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Fig. 8. Dissolution profiles of paclitaxel in PBS (pH 7.4) from A, B
paclitaxel powder as received and two different nanoparticle for-
mulations (NP), nanoparticle agglomerate formulations (NA) and F1
combination. C Dissolution profiles of cisplatin from cisplatin powder
as received and from F1 combination.
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5 mg/mL in A549 cells at the end of 12 h (Supplementary
Fig. 1A, B). The IC50 values for all other samples occurred at
concentrations higher than 1 mg/mL suggesting the safety of
these formulations for preclinical study (31).
CONCLUSION
Methods of lung cancer treatment have not changed
radically in recent history and the cure rate remains low.
Single drug or combined chemotherapy regimens including
cisplatin and paclitaxel may be recommended for non-small
cell lung cancer and local delivery of these agents may
ultimately improve the treatment of some types of lung
cancer. In this work, paclitaxel nanosuspensions were suc-
cessfully prepared via solvent precipitation in an aqueous
solution. These colloids were destabilized using L-leucine to
generate micron-sized agglomerates in a controlled fashion.
Nanoparticles and nanoparticle agglomerates revealed en-
hanced dissolution kinetics when compared to the drugs as
received. The nanoparticle agglomerate dry powders
exhibited aerosol characteristics and size distributions appro-
priate for pulmonary drug delivery. Moreover, the develop-
ment of paclitaxel nanoparticle agglomerates as a single agent
or in combination with cisplatin demonstrated a desirable
microstructure for efficient lung deposition and nanostructure
for rapid dissolution of the poorly water soluble paclitaxel. In
conclusion, this study offers an approach to localize combi-
nation lung cancer therapy using aerosolized nanoparticle
powders.
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